Resveratrol up-regulates SIRT1 and inhibits cellular oxidative stress in the diabetic milieu: Mechanistic insights

Journal of Nutritional Biochemistry

Volumn 23, Issue 7, 2012, Pages 699-705

  Yun, Jung Mi ^a   Chien, Alexander ^a   Jialal, Ishwarlal ^a   Devaraj, Sridevi ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

FOXO3a; Oxidative stress; P47phox; Resveratrol and diabetes; SIRT1

Indexed keywords

MANNITOL; PROTEIN P47; REACTIVE OXYGEN METABOLITE; RESVERATROL; SIRTUIN 1; SMALL INTERFERING RNA; SUPEROXIDE; TRANSCRIPTION FACTOR FKHRL1; TRANSCRIPTION FACTOR FOXO;

ARTICLE; CELL CULTURE; CELL PROTECTION; CONTROLLED STUDY; DEACETYLATION; HUMAN; HUMAN CELL; HUMAN MONOCYTIC EHRLICHIOSIS; HYPERGLYCEMIA; IN VITRO STUDY; INSULIN DEPENDENT DIABETES MELLITUS; MONOCYTE; OXIDATIVE STRESS; PHYTOCHEMISTRY; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN INTERACTION; UPREGULATION;

ANTIOXIDANTS; CELL LINE; DIABETES MELLITUS, TYPE 1; FORKHEAD TRANSCRIPTION FACTORS; HUMANS; MITOCHONDRIA; MONOCYTES; NADPH OXIDASE; OXIDATIVE STRESS; RNA, SMALL INTERFERING; SIRTUIN 1; STILBENES; SUPEROXIDES; UP-REGULATION;

MAMMALIA;

EID: 84862306635     PISSN: 09552863     EISSN: 18734847     Source Type: Journal    
DOI: 10.1016/j.jnutbio.2011.03.012     Document Type: Article

References (72)

1. Jialal I., Devaraj S., Venugopal S.K. Oxidative stress, inflammation, and diabetic vasculopathies: the role of alpha tocopherol therapy. Free Radic Res 2002, 6:1331-1336.
2. Jain S.K., Kannan K., Lim G., Matthew-Greer J., McVie R., Bocchini J.A. Elevated blood interleukin-6 levels in hyperketonemic type 1 diabetic patients and secretion by acetoacetate-treated cultured U937 monocytes. Diabetes Care 2003, 26:2139-2143.
3. Shanmugam N., Reddy M.A., Guha M., Natarajan R. High-glucose-induced expression of proinflammatory cytokine and chemokine genes in monocytic cells. Diabetes 2003, 52:1256-1264.
4. Igarashi M., Wakasaki H., Takahara N., Ishii H., Jiang Z.Y., Yamauchi T., et al. Glucose or diabetes activates p38 mitogen-activated protein kinase via different pathways. J Clin Invest 1999, 103:185-195.
5. Ceolotto G., Gallo A., Miola M., Sartori M., Trevisan R., Prato S.D., et al. Protein kinase C activity is acutely regulated by plasma glucose concentration in human monocytes in vivo. Diabetes 1999, 48:1316-1322.
6. Dandona P., Chaudhuri A., Ghanim H., Mohanty P. Proinflammatory effects of glucose and anti-inflammatory effect of insulin: relevance to cardiovascular disease. Am J Cardiol 2007, 99:15B-26B.
7. Hill H., Hogan N., Rallison M., Santos J.I., Charette R.P., Kitahara M. Functional and metabolic abnormalities of diabetic monocytes. Adv Exp Med Biol 1980, 69:621-627.
8. Yan S.F., Ramasamy R., Schmidt A.M. Mechanisms of disease: advanced glycation end-products and their receptor in inflammation and diabetes complications. Nat Clin Pract Endocrinol Metab 2008, 4:285-293.
9. Devaraj S., Venugopal S.K., Singh U., Jialal I. Hyperglycemia induces monocytic release of interleukin-6 via induction of protein kinase C-alpha and beta. Diabetes 2005, 54:85-91.
10. Beckman K.B., Ames B.N. The free radical theory of aging matures. Physiol Rev 1998, 78:547-581.
11. Venugopal S.K., Devaraj S., Yang T., Jialal I. α-Tocopherol decreases superoxide anion release in human monocytes under hyperglycemic conditions via inhibition of protein kinase C-α. Diabetes. 2002, 51(10):3049-3054.
12. Longo V.D., Kennedy B.K. Sirtuins in aging and age-related disease. Cell 2006, 126:257-268.
13. Marmorstein R. Structure and chemistry of the Sir2 family of NAD+-dependent histone/protein deactylases. Biochem Soc Trans 2004, 32:904-909.
14. Michan S., Sinclair D. Sirtuins in mammals: insights into their biological function. Biochem J 2007, 404:1-13.
15. Sauve A.A., Wolberger C., Schramm V.L., Boeke J.D. The biochemistry of sirtuins. Annu Rev Biochem 2006, 75:435-465.
16. Haigis M.C., Guarente L.P. Mammalian sirtuins-emerging roles in physiology, aging, and calorie restriction. Genes Dev 2006, 20:2913-2921.
17. Ying W. NAD+and NADH in cellular functions and cell death. Front Biosci 2006, 11:3129-3148.
18. Cheng H.L., Mostoslavsky R., Saito S., Manis J.P., Gu Y., Patel P., et al. Developmental defects and p53 hyperacetylation in Sir2 homolog (SIRT1)-deficient mice. Proc Natl Acad Sci USA 2003, 100:10794-10799.
19. Langley E., Pearson M., Faretta M., Bauer U.M., Frye R.A., Minucci S., et al. Human SIR2 deacetylates p53 and antagonizes PML/p53-induced cellular senescence. EMBO J. 2002, 21:2383-2396.
20. Luo J., Nikolaev A.Y., Imai S., Chen D., Su F., Shiloh A., et al. Negative control of p53 by Sir2alpha promotes cell survival under stress. Cell 2001, 19:137-148.
21. Vaziri H., Dessain S.K., Ng E.E., Imai S.I., Frye R.A., Pandita T.K., et al. hSIR2(SIRT1) functions as an NAD-dependent p53 deacetylase. Cell 2001, 19:149-159.
22. Brunet A., Sweeney L.B., Sturgill J.F., Chua K.F., Greer P.L., Lin Y., et al. Stress-dependent regulation of FOXO transcription factors by the SIRT1 deacetylase. Science 2004, 303:2011-2015.
23. Frescas D., Valenti L., Accili D. Nuclear trapping of the forkhead transcription factor FoxO1 via Sirt-dependent deacetylation promotes expression of glucogenetic genes. J Biol Chem 2005, 280:20589-20595.
24. Kobayashi Y., Furukawa-Hibi Y., Chen C., Horio Y., Isobe K., Ikeda K., et al. SIRT1 is critical regulator of FOXO-mediated transcription in response to oxidative stress. Int J Mol Med 2005, 16:237-243.
25. Li H., Liu J.P. Signaling on telomerase: a master switch in cell aging and immortalization. Biogerontology 2002, 3:107-116.
26. Yang Y., Hou H., Haller E.M., Nicosia S.V., Bai W. Suppression of FOXO1 activity by FHL2 through SIRT1-mediated deacetylation. EMBO J 2005, 24:1021-1032.
27. Balestrieri M.L., Rienzo M., Felice F., Rossiello R., Grimaldi V., Milone L., et al. High glucose downregulates endothelial progenitor cell number via SIRT1. Biochim Biophys Acta 2008, 1784:936-945.
28. Motta M.C., Divecha N., Lemieux M., Kamel C., Chen D., Gu W., et al. Mammalian SIRT1 represses forkhead transcription factors. Cell 2004, 116:551-563.
29. Hida Y., Kubo Y., Murao K., Arase S. Strong expression of a longevity-related protein, SIRT1, in Bowen's disease. Arch Dermatol Res 2007, 299:103-106.
30. Tikoo K., Tripathi D.N., Kabra D.G., Sharma V., Gaikwad A.B. Intermittent fasting prevents the progression of type I diabetic nephropathy in rats and changes the expression of Sir2 and p53. FEBS Lett 2007, 581:1071-1078.
31. Kim D., Nguyen M.D., Dobbin M.M., Fischer A., Sananbenesi F., Rodgers J.T., et al. SIRT1 deacetylase protects against neurodegeneration in models for Alzheimer's disease and amyotrophic lateral sclerosis. EMBO J 2007, 26:3169-3179.
32. Deng X.Q., Chen L.L., Li N.X. The expression of SIRT1 in nonalcoholic fatty liver disease induced by high-fat diet in rats. Liver Int 2007, 27:708-715.
33. de Kreutzenberg S.V., Ceolotto G., Papparella I., Bortoluzzi A., Semplicini A., Dalla Man C., et al. Downregulation of the longevity-associated protein sirtuin 1 in insulin resistance and metabolic syndrome: potential biochemical mechanisms. Diabetes 2010, 59(4):1006-1015.
34. Ota H., Eto M., Ogawa S., Iijima K., Akishita M., Ouchi Y. SIRT1/eNOS axis as a potential target against vascular senescence, dysfunction and atherosclerosis. Arterioscler Thromb Vasc Biol 2010, 30:2205-2211.
35. Milne J.C., Lambert P.D., Schenk S., Carney D.P., Smith J.J., Gagne D.J., et al. Small molecule activators of SIRT1 as therapeutics for the treatment of type 2 diabetes. Nature 2007, 450(7170):712-716.
36. Galili N., Davis R.J., Fredericks W.J., Mukhopadhyay S., Rauscher F.J., Emanuel B.S., et al. Fusion of a fork head domain gene to PAX3 in the solid tumour alveolar rhabdomyosarcoma. Nat Genet 1993, 5:230-235.
37. Anderson M.J., Viars C.S., Czekay S., Cavenee W.K., Arden K.C. Cloning and characterization of three human forkhead genes that comprise an FKHR-like gene subfamily. Genomics 1998, 47:187-199.
38. Parry P., Wei Y., Evans G. Cloning and characterization of the t(X;11) breakpoint from a leukemic cell line identify a new member of the forkhead gene family. Genes Chromosomes Cancer 1994, 11:79-84.
39. Jacobs F.M., van der Heide L.P., Wijchers P.J., Burbach J.P., Hoekman M.F., Smidt M.P. FoxO6, a novel member of the FoxO class of transcription factors with distinct shuttling dynamics. J Biol Chem 2003, 278:35959-35967.
40. Brunet A., Bonni A., Zigmond M.J., Lin M.Z., Juo P., Hu L.S., et al. Akt promotes cell survival by phosphorylating and inhibiting a Forkhead transcription factor. Cell. 1999, 96:857-868.
41. Giannakou M.E., Partridge L. The interaction between FOXO and SIRT1: tipping the balance towards survival. Trends Cell Biol 2004, 14:408-412.
42. Nemoto S., Finkel T. Redox regulation of forkhead proteins through a p66shc-dependent signaling pathway. Science 2002, 295:2450-2452.
43. Dijkers P.F. Forkhead transcription factor FKHR-L1 modulates cytokine-dependent transcriptional regulation of p27(KIP1). Mol Cell Biol 2000, 20:9138-9148.
44. Kops G.J., Dansen T.B., Polderman P.E., Saarloos I., Wirtz K.W., Coffer P.J., et al. Forkhead transcription factor FOXO3a protects quiescent cells from oxidative stress. Nature 2002, 419:316-321.
45. Pervaiz S. Resveratrol: from grapevines to mammalian biology. FASEB J 2003, 17(14):1975-1985.
46. Baur J.A., Pearson K.J., Price N.L., Jamieson H.A., Lerin C., Kalra A., et al. Resveratrol improves health and survival of mice on a high-calorie diet. Nature 2006, 444:337-342.
47. Baur J.A., Sinclair D.A. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006, 5:493-506.
48. Sharma S., Anjaneyulu M., Kulkarni S.K., Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006, 76:69-75.
49. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am J Physiol Endocrinol Metab 2006, 290:E1339-E1346.
50. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., et al. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic Biol Med 2007, 43:720-729.
51. Zang M., Xu S., Maitland-Toolan K.A., Zuccollo A., Hou X., Jiang B., et al. Polyphenols stimulate AMP-activated protein kinase, lower lipids, and inhibit accelerated atherosclerosis in diabetic LDL receptor-deficient mice. Diabetes 2006, 55:2180-2191.
52. Devaraj S., Dasu M.R., Rockwood J., Winter W., Griffen S.C., Jialal I. Increased toll-like receptor (TLR) 2 and TLR4 expression in monocytes from patients with type 1 diabetes: further evidence of a proinflammatory state. J Clin Endocrinol Metab 2008, 93(2):578-583.
53. Dasu M.R., Devaraj S., Jialal I. High glucose induces IL-1β expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 2007, 293:E337-E346.
54. Dasu M.R., Devaraj S., Du Clos T.W., Jialal I. The biological effects of CRP are not attributable to endotoxin contamination: evidence from TLR4 knockdown human aortic endothelial cells. J Lipid Res 2007, 48:509-512.
55. Dandona P., Thusu K., Cook S., Snyder B., Makowski J., Armstrong D., et al. Oxidative damage to DNA in diabetes mellitus. Lancet 1996, 347(8999):444-445.
56. Mohanty P., Hamouda W., Garg R., Aljada A., Ghanim H., Dandona P. Glucose challenge stimulates reactive oxygen species (ROS) generation by leucocytes. J Clin Endocrinol Metab 2000, 85(8):2970-2973.
57. Nemoto S., Fergusson M.M., Finkel T. Nutrient availability regulates SIRT1 through a forkhead-dependent pathway. Science 2004, 306:2105-2108.
58. Chaudhary N., Pfluger P.T. Metabolic benefits from Sirt1 and Sirt1 activators. Curr Opin Clin Nutr Metab Care 2009, 12(4):431-437.
59. Guarente L. sirtuins as potential targets for metabolic syndrome. Nature 2006, 444:868-874.
60. Jiang W.J. Sirtuins: novel targets for metabolic disease in drug development. Biochem Biophys Res Commun 2008, 373:341-344.
61. Van Der Heide L.P., Hoekman M.F., Smidt M.P. The ins and outs of FoxO shuttling: mechanisms of FoxO transcription and transcriptional regulations. Biochem. J. 2004, 380:297-309.
62. van der Horst A., Burgering B.M. Stressing the role of FOXO proteins in lifespan and disease. Nat. Rev. Mol. Cell Biol. 2007, 8:440.
63. Barthel A. FoxO proteins in insulin action and metabolism. Trends Endocrinol Metab 2005, 16:183-189.
64. Park C.E., Kim M.J., Lee J.H., Min B.I., Bae H., Choe W., et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 2007, 39(2):222-229.
65. Pearson K.J., Baur J.A., Lewis K.N., Peshkin L., Price N.L., Labinskyy N., et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008, 8:157-168.
66. Knutson M.D., Leeuwenburgh C. Resveratrol and novel potent activators of SIRT1: effects on aging and age-related diseases. Nutr Rev 2008, 66(10):591-596.
67. Hou X., Xu S., Maitland-Toolan K.A., Sato K., Jiang B., Ido Y., et al. SIRT1 regulates hepatocyte lipid metabolism through activating AMP-activated protein kinase. J Biol Chem 2008, 283(29):20015-20026.
68. Chow S.E., Hshu Y.C., Wang J.S., Chen J.K. Resveratrol attenuates oxLDL-stimulated NADPH oxidase activity and protects endothelial cells from oxidative functional damages. J Appl Physiol 2007, 102(4):1520-1527.
69. Park D.W., Baek K., Kim J.R., Lee J.J., Ryu S.H., Chin B.R., et al. Resveratrol inhibits foam cell formation via NADPH oxidase 1-mediated reactive oxygen species and monocyte chemotactic protein. Exp Mol Med 2009, 41(3):171-179.
70. Ungvari Z., Labinskyy N., Mukhopadhyay P., Pinto J.T., Bagi Z., Ballabh P., et al. Resveratrol attenuates mitochondrial oxidative stress in coronary arterial endothelial cells. Am J Physiol Heart Circ Physiol 2009, 297(5):H1876-H1881.
71. Orimo M., Minamino T., Miyauchi H., Tateno K., Okada S., Moriya J., et al. Protective role of SIRT1 in diabetic vascular dysfunction. Arterioscler Thromb Vasc Biol 2009, 29(6):889-894.
72. Ghanim H., Sia C.L., Abuaysheh S., Korzeniewski K., Patnaik P., Marumganti A., et al. An antiinflammatory and reactive oxygen species suppressive effects of an extract of Polygonum cuspidatum containing resveratrol. J Clin Endocrinol Metab 2010, 95(9):E1-E8.